IRulya Therapeutics IRLA Chief Financial Officer · filings 2026 to 2026
No transactions in the filings read; Form 144 notices are listed above.
Person · CIK 1662170
John Militello
Chief Financial Officer at IRulya Therapeutics; Controller at Rocket Pharmaceuticals
Earlier: Immune Pharmaceuticals
Sold on Form 4$903K
Noticed on Form 144$969K
Bought on Form 4$0
Companies3
Holdings now
As reported after the latest Form 3, 4 or 5 at each company.
How these figures work
Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.
| Company | Security | Held | Shares or units | As of |
|---|---|---|---|---|
| Rocket Pharmaceuticals RCKT | Common Stock | Directly | 89,780 | May 19, 2026 · Filing · EDGAR |
| Rocket Pharmaceuticals RCKT | Stock Option (Right to Buy) exercise $3.00, expires May 26, 2031, into Common Stock | Directly | 51,509 | May 26, 2026 · Filing · EDGAR |
| Rocket Pharmaceuticals RCKT | Stock Option (Right to Buy) exercise $3.00, expires Feb 14, 2033, into Common Stock | Directly | 24,899 | May 26, 2026 · Filing · EDGAR |
| Rocket Pharmaceuticals RCKT | Stock Option (Right to Buy) exercise $3.00, expires Apr 18, 2032, into Common Stock | Directly | 16,061 | May 26, 2026 · Filing · EDGAR |
| Rocket Pharmaceuticals RCKT | Stock Option (Right to Buy) exercise $3.00, expires Feb 14, 2032, into Common Stock | Directly | 15,002 | May 26, 2026 · Filing · EDGAR |
| Rocket Pharmaceuticals RCKT | Stock Option (Right to Buy) exercise $3.00, expires Feb 16, 2034, into Common Stock | Directly | 9,091 | May 26, 2026 · Filing · EDGAR |
| Immune Pharmaceuticals | Common Stock | Directly | 2,000 | Dec 31, 2015 · Filing · EDGAR |
Sold and noticed by quarter
Sold (Form 4) Noticed (Form 144) Bought (Form 4)
Quarterly totals as a table
| Quarter | Sold (Form 4) | Noticed (Form 144) |
|---|---|---|
| Q3 2026 | — | $80K |
| Q2 2026 | $4K | $4K |
| Q1 2026 | $16K | $16K |
| Q4 2025 | $118K | $118K |
| Q3 2025 | $24K | $24K |
| Q2 2025 | $12K | $12K |
| Q1 2025 | $38K | $38K |
| Q4 2024 | $31K | $31K |
| Q3 2024 | $38K | $38K |
| Q2 2024 | $44K | $44K |
| Q1 2024 | $482K | $482K |
| Q4 2023 | $10K | $15K |
| Q3 2023 | $15K | $15K |
| Q2 2023 | $49K | $49K |
| Q1 2023 | $21K | Not machine-readable |
Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.
Planned sales (Form 144) and the sales that followed
Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.
How we match
A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.
| Notice date | Noticed | Planned sale | Outcome | Links |
|---|---|---|---|---|
| Rocket Pharmaceuticals RCKT · Fidelity Brokerage Services · No 10b5-1 plan stated · 34 notices | ||||
| Sep 15, 2026 | 6,897 · ~$23K | Sep 15, 2026 | Not sold yet | Filing · EDGAR |
| Sep 14, 2026 | 6,857 · ~$23K | Sep 14, 2026 | Not sold yet | Filing · EDGAR |
| Sep 11, 2026 | 8,923 · ~$30K | Sep 11, 2026 | Not sold yet | Filing · EDGAR |
| Aug 18, 2026 | 1,252 · ~$4K | Aug 18, 2026 | Not sold yet | Filing · EDGAR |
| May 19, 2026 | 384 · ~$1K | May 19, 2026 | Sold as noticed Sold 384 at $3.01 on May 19 · $1K Form 4 | Filing · EDGAR |
| May 13, 2026 | 855 · ~$3K | May 13, 2026 | Sold as noticed Sold 855 at $3.61 on May 13 · $3K Form 4 | Filing · EDGAR |
| Feb 18, 2026 | 1,157 · ~$4K | Feb 18, 2026 | Sold as noticed Sold 1,157 at $3.34 on Feb 18 · $4K Form 4 | Filing · EDGAR |
| Feb 13, 2026 | 3,726 · ~$12K | Feb 13, 2026 | Sold as noticed Sold 3,726 at $3.31 on Feb 13 · $12K Form 4 | Filing · EDGAR |
| Nov 18, 2025 | 1,086 · ~$3K | Nov 18, 2025 | Sold as noticed Sold 1,086 at $2.98 on Nov 18 · $3K Form 4 | Filing · EDGAR |
| Oct 14, 2025 | 28,918 · ~$115K | Oct 14, 2025 | Sold as noticed Sold 28,918 in 4 sales, Oct 14 to Oct 14 · $115K Form 4 | Filing · EDGAR |
| Aug 19, 2025 | 361 · ~$1K | Aug 19, 2025 | Sold as noticed Sold 361 at $3.00 on Aug 19 · $1K Form 4 | Filing · EDGAR |
| Aug 18, 2025 | 699 · ~$2K | Aug 18, 2025 | Sold as noticed Sold 699 at $3.07 on Aug 18 · $2K Form 4 | Filing · EDGAR |
| Aug 14, 2025 | 7,043 · ~$21K | Aug 14, 2025 | Sold as noticed Sold 7,043 at $3.02 on Aug 14 · $21K Form 4 | Filing · EDGAR |
| May 20, 2025 | 357 · ~$2K | May 20, 2025 | Sold as noticed Sold 357 at $6.45 on May 20 · $2K Form 4 | Filing · EDGAR |
| May 16, 2025 | 655 · ~$4K | May 16, 2025 | Sold as noticed Sold 655 at $6.53 on May 16 · $4K Form 4 | Filing · EDGAR |
| Apr 22, 2025 | 718 · ~$5K | Apr 22, 2025 | Sold as noticed Sold 718 at $7.16 on Apr 22 · $5K Form 4 | Filing · EDGAR |
| Feb 21, 2025 | 2,737 · ~$29K | Feb 21, 2025 | Sold as noticed Sold 2,737 at $10.58 on Feb 21 · $29K Form 4 | Filing · EDGAR |
| Jan 23, 2025 | 896 · ~$9K | Jan 23, 2025 | Sold as noticed Sold 896 at $10.38 on Jan 23 · $9K Form 4 | Filing · EDGAR |
| Nov 21, 2024 | 1,224 · ~$16K | Nov 21, 2024 | Sold as noticed Sold 1,224 at $13.05 on Nov 21 · $16K Form 4 | Filing · EDGAR |
| Oct 31, 2024 | 917 · ~$15K | Oct 31, 2024 | Sold as noticed Sold 917 at $16.63 on Oct 31 · $15K Form 4 | Filing · EDGAR |
| Aug 16, 2024 | 1,064 · ~$20K | Aug 16, 2024 | Sold as noticed Sold 1,064 at $18.50 on Aug 16 · $20K Form 4 | Filing · EDGAR |
| Jul 22, 2024 | 812 · ~$19K | Jul 22, 2024 | Sold as noticed Sold 812 at $23.02 on Jul 22 · $19K Form 4 | Filing · EDGAR |
| May 16, 2024 | 1,079 · ~$25K | May 16, 2024 | Sold as noticed Sold 1,079 at $23.35 on May 16 · $25K Form 4 | Filing · EDGAR |
| Apr 22, 2024 | 833 · ~$19K | Apr 22, 2024 | Sold as noticed Sold 833 at $22.87 on Apr 22 · $19K Form 4 | Filing · EDGAR |
| Mar 21, 2024 | 2,490 · ~$70K | Mar 21, 2024 | Sold as noticed Sold 2,490 at $28.10 on Mar 21 · $70K Form 4 | Filing · EDGAR |
| Feb 29, 2024 | 10,000 · ~$298K | Feb 29, 2024 | Sold as noticed Sold 10,000 at $29.85 on Feb 29 · $298K Form 4 | Filing · EDGAR |
| Feb 16, 2024 | 3,238 · ~$97K | Feb 16, 2024 | Sold as noticed Sold 3,238 at $29.84 on Feb 16 · $97K Form 4 | Filing · EDGAR |
| Jan 22, 2024 | 638 · ~$17K | Jan 22, 2024 | Sold as noticed Sold 638 at $27.20 on Jan 22 · $17K Form 4 | Filing · EDGAR |
| Nov 16, 2023 | 274 · ~$6K | Nov 16, 2023 | Not sold within 90 days | Filing · EDGAR |
| Oct 20, 2023 | 564 · ~$10K | Oct 20, 2023 | Sold as noticed Sold 564 at $17.06 on Oct 20 · $10K Form 4 | Filing · EDGAR |
| Aug 17, 2023 | 284 · ~$4K | Aug 17, 2023 | Sold as noticed Sold 284 at $15.47 on Aug 17 · $4K Form 4 | Filing · EDGAR |
| Jul 20, 2023 | 573 · ~$11K | Jul 20, 2023 | Sold as noticed Sold 573 at $19.03 on Jul 20 · $11K Form 4 | Filing · EDGAR |
| May 17, 2023 | 245 · ~$5K | May 17, 2023 | Sold as noticed Sold 245 at $21.38 on May 17 · $5K Form 4 | Filing · EDGAR |
| Apr 21, 2023 | 2,342 · ~$44K | Apr 21, 2023 | Sold as noticed Sold 2,342 at $18.65 on Apr 21 · $44K Form 4 | Filing · EDGAR |
| Sales without a matching Form 144 · 1 sale No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt. | ||||
| — | — | — | Notice not machine-readable Rocket Pharmaceuticals (RCKT): Sold 1,076 at $19.06 on Feb 17, 2023 · $21K | Filing · EDGAR |
Every transaction, by company
Each Form 3, 4 and 5 transaction in plain words, newest first.
How these figures work
Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.
Rocket Pharmaceuticals RCKT Controller, Principal Financial Officer and Principal Accounting Officer // Exhibit List - Exhibit 24 - Powers of Attorney · filings 2018 to 2026 · sold $903K · $969K noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| May 26, 2026 | Returned to the company Stock Option (Right to Buy) | −10,000 | 0 direct | Filing · EDGAR | ||
| May 26, 2026 | Returned to the company Stock Option (Right to Buy) | −10,000 | 0 direct | Filing · EDGAR | ||
| May 26, 2026 | Returned to the company Stock Option (Right to Buy) | −20,000 | 0 direct | Filing · EDGAR | ||
| May 26, 2026 | Returned to the company Stock Option (Right to Buy) | −10,000 | 0 direct | Filing · EDGAR | ||
| May 26, 2026 | Returned to the company Stock Option (Right to Buy) | −20,000 | 0 direct | Filing · EDGAR | ||
| May 26, 2026 | Returned to the company Stock Option (Right to Buy) | −2,000 | 0 direct | Filing · EDGAR | ||
| May 26, 2026 | Returned to the company Stock Option (Right to Buy) | −18,000 | 0 direct | Filing · EDGAR | ||
| May 26, 2026 | Returned to the company Stock Option (Right to Buy) | −18,000 | 0 direct | Filing · EDGAR | ||
| May 26, 2026 | Returned to the company Stock Option (Right to Buy) | −27,003 | 0 direct | Filing · EDGAR | ||
| May 26, 2026 | Returned to the company Stock Option (Right to Buy) | −28,910 | 0 direct | Filing · EDGAR | ||
| May 26, 2026 | Returned to the company Stock Option (Right to Buy) | −49,798 | 0 direct | Filing · EDGAR | ||
| May 26, 2026 | Returned to the company Stock Option (Right to Buy) | −24,545 | 0 direct | Filing · EDGAR | ||
| May 26, 2026 | Grant or award from the company Stock Option (Right to Buy) | +51,509 | 51,509 direct | Filing · EDGAR | ||
| May 26, 2026 | Grant or award from the company Stock Option (Right to Buy) | +15,002 | 15,002 direct | Filing · EDGAR | ||
| May 26, 2026 | Grant or award from the company Stock Option (Right to Buy) | +16,061 | 16,061 direct | Filing · EDGAR | ||
| May 26, 2026 | Grant or award from the company Stock Option (Right to Buy) | +24,899 | 24,899 direct | Filing · EDGAR | ||
| May 26, 2026 | Grant or award from the company Stock Option (Right to Buy) | +9,091 | 9,091 direct | Filing · EDGAR | ||
| May 19, 2026 | Open-market or private sale | −384 | $3.01 | $1K | 89,780 direct | Filing · EDGAR |
| May 13, 2026 | Open-market or private sale | −855 | $3.61 | $3K | 90,164 direct | Filing · EDGAR |
| Feb 18, 2026 | Open-market or private sale | −1,157 | $3.34 | $4K | 91,019 direct | Filing · EDGAR |
| Feb 13, 2026 | Open-market or private sale | −3,726 | $3.31 | $12K | 92,176 direct | Filing · EDGAR |
| Feb 11, 2026 | Grant or award from the company | +29,982 | 95,902 direct | Filing · EDGAR | ||
| Feb 11, 2026 | Grant or award from the company Stock Option (Right to Buy) | +45,018 | 45,018 direct | Filing · EDGAR | ||
| Nov 18, 2025 | Open-market or private sale | −1,086 | $2.98 | $3K | 65,920 direct | Filing · EDGAR |
| Oct 14, 2025 | Open-market or private sale | −19,841 | $3.96 | $79K | 76,083 direct | Filing · EDGAR |
| Oct 14, 2025 | Open-market or private sale | −5,514 | $3.97 | $22K | 70,569 direct | Filing · EDGAR |
| Oct 14, 2025 | Open-market or private sale | −3,005 | $3.97 | $12K | 67,564 direct | Filing · EDGAR |
| Oct 14, 2025 | Open-market or private sale | −558 | $3.98 | $2K | 67,006 direct | Filing · EDGAR |
| Sep 8, 2025 | Grant or award from the company | +40,000 | 95,924 direct | Filing · EDGAR | ||
| Aug 19, 2025 | Open-market or private sale | −361 | $3.00 | $1K | 55,924 direct | Filing · EDGAR |
| Aug 18, 2025 | Open-market or private sale | −699 | $3.07 | $2K | 56,285 direct | Filing · EDGAR |
| Aug 14, 2025 | Open-market or private sale | −7,043 | $3.02 | $21K | 56,984 direct | Filing · EDGAR |
| May 20, 2025 | Open-market or private sale | −357 | $6.45 | $2K | 64,027 direct | Filing · EDGAR |
| May 16, 2025 | Open-market or private sale | −655 | $6.53 | $4K | 64,384 direct | Filing · EDGAR |
| Apr 22, 2025 | Open-market or private sale | −718 | $7.16 | $5K | 65,039 direct | Filing · EDGAR |
| Feb 21, 2025 | Open-market or private sale | −2,737 | $10.58 | $29K | 65,757 direct | Filing · EDGAR |
| Feb 11, 2025 | Grant or award from the company | +20,080 | 68,494 direct | Filing · EDGAR | ||
| Feb 11, 2025 | Grant or award from the company Stock Option (Right to Buy) | +29,920 | 29,920 direct | Filing · EDGAR | ||
| Jan 23, 2025 | Open-market or private sale | −896 | $10.38 | $9K | 48,414 direct | Filing · EDGAR |
| Nov 21, 2024 | Open-market or private sale | −1,224 | $13.05 | $16K | 49,310 direct | Filing · EDGAR |
| Oct 31, 2024 | Open-market or private sale | −917 | $16.63 | $15K | 50,534 direct | Filing · EDGAR |
| Aug 16, 2024 | Open-market or private sale | −1,064 | $18.50 | $20K | 51,451 direct | Filing · EDGAR |
| Jul 22, 2024 | Open-market or private sale | −812 | $23.02 | $19K | 52,515 direct | Filing · EDGAR |
| May 16, 2024 | Open-market or private sale | −1,079 | $23.35 | $25K | 53,327 direct | Filing · EDGAR |
| Apr 22, 2024 | Open-market or private sale | −833 | $22.87 | $19K | 54,406 direct | Filing · EDGAR |
| Mar 21, 2024 | Open-market or private sale | −2,490 | $28.10 | $70K | 55,239 direct | Filing · EDGAR |
| Feb 29, 2024 | Option or RSU exercised or converted | +10,000 | $12.55 | $126K | 31,517 direct | Filing · EDGAR |
| Feb 29, 2024 | Open-market or private sale | −10,000 | $29.85 | $298K | 21,517 direct | Filing · EDGAR |
| Feb 29, 2024 | Option or RSU exercised or converted Stock Option (Right to Buy) | −10,000 | $12.55 | $126K | 0 direct | Filing · EDGAR |
| Feb 16, 2024 | Open-market or private sale | −3,238 | $29.84 | $97K | 13,195 direct | Filing · EDGAR |
| Feb 16, 2024 | Grant or award from the company | +8,322 | 21,517 direct | Filing · EDGAR | ||
| Feb 16, 2024 | Grant or award from the company Stock Option (Right to Buy) | +24,545 | 24,545 direct | Filing · EDGAR | ||
| Feb 14, 2024 | Option or RSU exercised or converted | +6,274 | 16,433 direct | Filing · EDGAR | ||
| Feb 14, 2024 | Option or RSU exercised or converted Restricted Stock Units | −725 | 2,903 direct | Filing · EDGAR | ||
| Feb 14, 2024 | Option or RSU exercised or converted Restricted Stock Units | −5,549 | 10,159 direct | Filing · EDGAR | ||
| Jan 22, 2024 | Open-market or private sale | −638 | $27.20 | $17K | 10,159 direct | Filing · EDGAR |
| Jan 18, 2024 | Option or RSU exercised or converted | +1,586 | 10,797 direct | Filing · EDGAR | ||
| Jan 18, 2024 | Option or RSU exercised or converted Restricted Stock Units | −1,586 | 7,932 direct | Filing · EDGAR | ||
| Nov 14, 2023 | Option or RSU exercised or converted | +725 | 9,485 direct | Filing · EDGAR | ||
| Nov 14, 2023 | Option or RSU exercised or converted Restricted Stock Units | −725 | 3,628 direct | Filing · EDGAR |
41 earlier transactions are in the filing list below.
Immune Pharmaceuticals Vice President of Finance, Controller and Chief Accounting Officer (Principal Financial Officer) · filings 2016 to 2016
All 92 Forms 3, 4, 5 and 144
Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.